Welcome to our dedicated page for Avantor SEC filings (Ticker: AVTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Avantor's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Avantor's regulatory disclosures and financial reporting.
Makin Louise reported acquisition or exercise transactions in this Form 4 filing.
Avantor, Inc. director Louise Makin received an equity award of 25,270 shares of common stock in the form of restricted stock units. The award was granted at a stated price of $0.00 per share as part of compensation rather than a market purchase or sale.
The restricted stock units are scheduled to vest on May 7, 2027, meaning the shares will be delivered only if the vesting conditions are met. Following this grant, Makin directly holds a total of 47,140 shares of Avantor common stock, indicating the transaction is an automatic, non-market equity grant.
Massaro Joseph R reported acquisition or exercise transactions in this Form 4 filing.
Avantor director Joseph R. Massaro received a compensation-related stock grant. He was awarded 25,270 shares of Avantor common stock on May 7, 2026 as a grant or award, rather than a market purchase. The shares are in the form of restricted stock units that vest on May 7, 2027.
After this grant, Massaro directly owns 77,408 shares of Avantor common stock. This filing reflects an equity-based compensation decision by the company’s board, not an open-market transaction.
Avantor, Inc. director Sanjeev K. Mehra reported an equity compensation grant. He received 25,270 shares of common stock in the form of restricted stock units at no cash cost, classified as a grant or award acquisition.
The restricted stock units vest on May 07, 2027, meaning he will fully earn the shares on that date if vesting conditions are met. After this grant, Mehra directly holds 33,376 shares of Avantor common stock.
The filing also notes 475,000 shares of common stock held indirectly through a limited liability company. Mehra disclaims beneficial ownership of these indirectly held securities except to the extent of any pecuniary interest.
SEVERINO MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Avantor director Michael Severino reported a compensation grant of 25,270 shares of Common Stock in the form of restricted stock units that vest on May 7, 2027. The award carries no purchase price and increases his direct holdings to 85,821 shares, reflecting routine equity-based board compensation rather than an open-market share purchase.
SUMME GREGORY L reported acquisition or exercise transactions in this Form 4 filing.
Avantor, Inc. director Gregory L. Summe reported an equity award and updated holdings. He received a grant of 25,270 shares of common stock in the form of restricted stock units, with no cash paid per share. According to the footnote, these restricted stock units vest on May 7, 2027. After this award, he directly holds 83,381 shares and indirectly holds 400,000 shares through a trust, giving a clearer picture of both his compensation and total reported ownership.
Avantor, Inc. director Simon Dingemans reported an open-market purchase of 25,000 shares of Common Stock. The trade was executed at a price of $8.14 per share and is reported as indirect ownership "By Spouse", meaning the shares are held by his spouse but attributed to him for reporting.
The filing also shows Dingemans with 6,225 shares of Common Stock held directly as of the same date in a separate holding entry. There are no derivative securities reported, so this update reflects only common stock ownership.
Avantor, Inc. executive Ludovic Brellier, EVP, Bioscience & Medtech, received new equity awards. He was granted 146,566 shares of common stock in the form of restricted stock units that vest in three equal annual installments beginning on May 1, 2027. Following this grant, he holds 146,566 common shares directly. He also received 246,002 stock options to buy common stock at an exercise price of $8.76 per share, which vest in three equal annual installments starting on May 1, 2027 and expire on May 1, 2036. These awards are part of his compensation, not open-market purchases or sales.
Avantor, Inc. executive Ludovic Brellier, EVP of Bioscience & Medtech, has filed an initial Form 3 reporting his status as an insider. The provided data shows no buy, sell, or other share transactions and no derivative positions reported in this filing excerpt.
Avantor Inc reported that Vanguard Capital Management beneficially owns 35,802,263 shares of Common Stock, equal to 5.29% of the class. The filing states Vanguard Capital Management has sole dispositive power over 35,802,263 shares and sole voting power over 5,196,151 shares.
The disclosure names affiliated Vanguard entities that exercise voting or dispositive power for certain holdings and is signed by Ashley Grim, Head of Global Fund Administration.